Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Contemp Clin Trials. 2011 Mar;32(2):240-3. doi: 10.1016/j.cct.2010.11.004. Epub 2010 Nov 9.

    The blind leading the blind: use and misuse of blinding in randomized controlled trials.

    Source

    Research and Clinical Services, Sprim Advanced Life Sciences, 235 Pine Street, Suite 1175, San Francisco, CA 94104, United States. larry.miller@sprim.com

    Abstract

    The use of blinding strengthens the credibility of randomized controlled trials (RCTs) by minimizing bias. However, there is confusion surrounding the definition of blinding as well as the terms single, double, and triple blind. It has been suggested that these terms should be discontinued due to their broad misinterpretation. We recommend that, instead of abandoning the use of these terms, explicit definitions of blinding should be adopted. We address herein the concept of blinding, propose standard definitions for the consistent use of these terms, and detail when different types of blinding should be utilized. Standardizing the definition of blinding and utilizing proper blinding methods will improve the quality and clarity of reporting in RCTs.

    Copyright © 2010 Elsevier Inc. All rights reserved.

    PMID:
    21070890
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk